Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
Hualan Biological Engineering Inc. (SHE: 002007) announced on September 8, 2026 that its novel influenza...
mRNA
Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases
Typewriter Therapeutics announced the completion of a USD 56 million Series A financing to develop...
GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots
GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal...
METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
METiS TechBio (HKG: 7666) and WestVac Biopharma, an innovative vaccine and immunotherapy company led by...
Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
Starna Therapeutics, a clinical-stage mRNA drug developer based in Suzhou, announced the completion of a...
Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced it has received clinical trial approval from China’s...
Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates
Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China’s National Medical Products...
Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that the U.S. Food and Drug Administration...
YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration
YolTech Therapeutics, a China‑based mRNA therapy and gene therapy developer, announced a strategic partnership with...
Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia
Moderna Inc. (NASDAQ: MRNA) announced a global partnership with Italy‑based Recordati for mRNA-3927, an investigational mRNA...
Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform
Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment...
Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline
Byterna Therapeutics completed its angel plus round financing, exclusively invested by Efung Capital. Proceeds will...
Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine
Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum...
Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina
Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...
Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization
Chengdu Westgene Biopharma announced the establishment of a strategic partnership with Shenzhen BGI Huo-Yan Engineering...
BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies
Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...
CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials
China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...
Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...
AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design
China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...
Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials
Beijing-based cell therapy developer Likang Life Sciences announced that it has received approval from the...